Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has 4 years of Other Non-Current Liabilities data on file, last reported at $35.6 million in Q2 2024.

• On a quarterly basis, Other Non-Current Liabilities rose 2596.67% year-over-year to $35.6 million in Q2 2024; TTM through Jun 2024 was $35.6 million, a 2596.67% increase from a year earlier, with the FY2023 full-year figure at $1.2 million, down 14.18% from the prior year.
• Other Non-Current Liabilities for Q2 2024 stood at $35.6 million, up from $34.6 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for RYTM reached as high as $35.6 million in Q2 2024 and fell as low as $1000.0 in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $8.6 million across 3 years, with a median of $1.3 million in 2023.
• Across the five-year window, Other Non-Current Liabilities slipped 16.98% in 2023 and soared 3459700.0% in 2024, its largest moves.
• Year by year, Other Non-Current Liabilities stood at $1.3 million in 2022, then retreated by 14.18% to $1.2 million in 2023, then surged by 2995.3% to $35.6 million in 2024.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $35.6 million in Q2 2024, $34.6 million in Q1 2024, and $1.2 million in Q4 2023.